Trial Profile
Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Trenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Registrational; Therapeutic Use
- Sponsors Medexus Pharmaceuticals
- 08 Mar 2024 According to a XOMA media release, Medexus Pharmaceuticals has submitted pediatric label expansion application for IXINITY which has been accepted for review by FDA. FDA decision expected in 2024.
- 26 Aug 2022 Status changed from active, no longer recruiting to completed.
- 30 Aug 2021 Planned End Date changed from 1 Sep 2021 to 30 Jul 2022.